跳至主要内容
临床试验/NL-OMON43321
NL-OMON43321已完成不适用

The effect of curcumin and piperine on the pharmacokinetics of tamoxifen in patients with breast cancer *the ELDORADO study* - The ELDORADO-study

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 17 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
17

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Age * 18 years;2. Histological or cytological confirmed diagnosis of breast cancer in patients with an indication for tamoxifen treatment.;3. WHO Performance Status * 1 ;4. Able and willing to sign the Informed Consent Form prior to screening evaluations;5. Abstain from curry, grapefruit (juice), (herbal) dietary supplements besides curcumin, herbals, over-the-counter medication (except for paracetamol and ibuprofen).;6. Adequate baseline patient characteristics (complete blood count, and serum biochemistry which involves sodium, potassium, creatinin, calculation of creatinin clearance (MDRD), AST, ALT, gamma glutamyltranspeptidase (GGT), lactate dehydrogenase (LDH), ALP, total bilirubin, albumin).

排除标准

  • 1. Pregnant or lactating patients.;2. Patients with known impaired drug absorption (e.g. gastrectomy and achlorhydria).;3. Use of other drugs, which are mainly dependent for their metabolism on CYP3A4 and CYP2D6. ;4. Known serious illness or medical unstable conditions that could interfere with this study; requiring treatment (e.g. infection, bleedings, uncontrolled hypertension despite optimal medical management, HIV, hepatitis, organ transplants, kidney, cardiac and respiratory diseases).;5. Bilirubin CTCAE grade 2 or higher, ASAT/ALAT CTCAE grade 2 or higher and grade 3 or higher in patients with liver metastasis. . Renal function impairment CTCAE grade 2 or higher.;6. Symptomatic CNS metastases or history of psychiatric disorder that would prohibit the understanding and giving of informed consent.;7. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation. ;8. Patients on strong CYP3A4 or CYP2D6 inhibitors or inducers, P-gp substrates or medication or supplements which can interact with tamoxifen and curcumin are not eligible for the study.

研究者

相似试验